Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China
· Delayed Price · Currency is CNY 2.820
-0.090 (-3.09%)
Apr 28, 2025, 2:45 PM CST
SHE:002589 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 41.02 | 20.32 | -1,831 | 131.18 | 261.3 | Upgrade
|
| Depreciation & Amortization | 199.14 | 184.28 | 283.88 | 319.22 | 291.41 | Upgrade
|
| Other Amortization | 16.91 | 61.16 | 32.88 | 44.42 | 46.39 | Upgrade
|
| Loss (Gain) From Sale of Assets | -18.94 | 7.92 | 1 | -3.06 | -3.78 | Upgrade
|
| Asset Writedown & Restructuring Costs | -30.03 | 4.91 | 47.83 | 39.9 | 25.43 | Upgrade
|
| Loss (Gain) From Sale of Investments | -96.21 | -424.59 | 656.44 | -103.46 | -226.57 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 10.01 | 159.22 | 158.77 | 123.63 | Upgrade
|
| Other Operating Activities | 263.48 | 651.21 | 1,036 | 822.64 | 1,031 | Upgrade
|
| Change in Accounts Receivable | 61.01 | 1,122 | -6,340 | -197.21 | -198.13 | Upgrade
|
| Change in Inventory | 385.04 | -165.26 | 190.72 | 476.9 | 377.99 | Upgrade
|
| Change in Accounts Payable | -660.28 | -1,219 | 6,314 | -1,069 | -1,254 | Upgrade
|
| Operating Cash Flow | 160.44 | 82.47 | 523.07 | 442.95 | 414.96 | Upgrade
|
| Operating Cash Flow Growth | 94.56% | -84.23% | 18.09% | 6.75% | -80.19% | Upgrade
|
| Capital Expenditures | -111.53 | -298.38 | -170.96 | -461.09 | -640.15 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.75 | 0.71 | 83.97 | 13.35 | 2.19 | Upgrade
|
| Cash Acquisitions | - | - | -70.37 | -173.27 | -358.5 | Upgrade
|
| Divestitures | 226.27 | 1,163 | 982.53 | 82.08 | 313.89 | Upgrade
|
| Investment in Securities | 90.44 | -285.98 | -297.63 | -80.58 | -491.53 | Upgrade
|
| Other Investing Activities | -1.96 | 0.3 | 32.77 | 20.44 | 26.81 | Upgrade
|
| Investing Cash Flow | 203.98 | 579.53 | 592.96 | -583.51 | -972.71 | Upgrade
|
| Short-Term Debt Issued | - | 5,656 | 6,271 | 8,480 | 8,531 | Upgrade
|
| Long-Term Debt Issued | 2,713 | 20,535 | 11,159 | 11,066 | 13,059 | Upgrade
|
| Total Debt Issued | 2,713 | 26,191 | 17,430 | 19,547 | 21,591 | Upgrade
|
| Short-Term Debt Repaid | - | -22,609 | -14,030 | -12,372 | -3,460 | Upgrade
|
| Long-Term Debt Repaid | -2,961 | -3,975 | -4,347 | -6,824 | -9,802 | Upgrade
|
| Total Debt Repaid | -2,961 | -26,584 | -18,377 | -19,196 | -13,261 | Upgrade
|
| Net Debt Issued (Repaid) | -248.48 | -393.11 | -947.42 | 350.84 | 8,330 | Upgrade
|
| Issuance of Common Stock | - | 26.3 | 68.7 | 4.24 | 8.56 | Upgrade
|
| Repurchase of Common Stock | - | -28.54 | -29.58 | -4.4 | -8.03 | Upgrade
|
| Common Dividends Paid | -198.71 | -201.69 | -154.31 | -316.31 | -346.56 | Upgrade
|
| Other Financing Activities | 300.72 | -80.15 | -402.52 | -84.78 | -9,065 | Upgrade
|
| Financing Cash Flow | -146.47 | -677.2 | -1,465 | -50.42 | -1,081 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | -0 | 0 | -0 | 0 | Upgrade
|
| Net Cash Flow | 217.95 | -15.2 | -349.09 | -190.98 | -1,639 | Upgrade
|
| Free Cash Flow | 48.92 | -215.92 | 352.11 | -18.13 | -225.19 | Upgrade
|
| Free Cash Flow Margin | 0.61% | -2.69% | 2.86% | -0.09% | -0.83% | Upgrade
|
| Free Cash Flow Per Share | 0.03 | -0.14 | 0.24 | -0.01 | -0.15 | Upgrade
|
| Cash Interest Paid | - | 19.57 | 36.58 | 43.35 | 0.3 | Upgrade
|
| Cash Income Tax Paid | 165.85 | 135.3 | 398.68 | 928.46 | 1,055 | Upgrade
|
| Levered Free Cash Flow | 114.49 | -3,705 | 4,920 | 5,678 | -2,201 | Upgrade
|
| Unlevered Free Cash Flow | 114.49 | -3,516 | 5,175 | 6,024 | -1,817 | Upgrade
|
| Change in Net Working Capital | 37.69 | 3,429 | -5,097 | -5,613 | 2,403 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.